Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Report - MDSpire
Advertisement
Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors
Clinical Report: Erratum on Phase I/II Study of Durvalumab and Tremelimumab
Overview
This report addresses a correction in the Phase I/II study evaluating durvalumab and tremelimumab in pediatric patients with advanced solid tumors. The erratum highlights misalignment in data presentation and missing footnotes in the original publication.
Background
The study of durvalumab and tremelimumab is significant as it explores dual checkpoint blockade in pediatric patients with relapsed/refractory solid tumors. Accurate data representation is crucial for the interpretation of clinical trial results, which can impact future research and treatment protocols in this vulnerable population.
Data Highlights
Correction Details
Misalignment of numerical values in Table 1
Missing footnote for histology terms
Key Findings
Correction of misaligned numerical values in Table 1.
Missing footnote regarding histology terms was identified.
ETRAN, MPNST, and UCNT were defined in the context of tumor types.
The original article has been updated to reflect these corrections.
Clinical Implications
Clinicians should refer to the corrected data for accurate information regarding the study outcomes. Ensuring the integrity of clinical trial data is essential for guiding treatment decisions in pediatric oncology.
Conclusion
The erratum serves to clarify previous inaccuracies in the study's data presentation, reinforcing the importance of precise reporting in clinical research.
